meta|Evidence - COVID-19
click on circles to display study description...
acalabrutinib (n=70) vs. standard of care (n=70)
randomized controlled trial risk of bias NA
acalabrutinib
standard of care
COVID 19 hospitalized
open label
1 center, Argentina
acalabrutinib (n=31) vs. standard of care (n=31)
randomized controlled trial risk of bias NA
acalabrutinib
standard of care
COVID 19 hospitalized
open label
multicenters, USA
imatinib (n=55) vs. lopinavir/ritonavir plus chloroquine (n=-9)
randomized controlled trial risk of bias NA
-lopinavir/ ritonavir hydroxychloroquine-imatinib hydroxychloroquine-baricitinib hydroxychloroquine
no formal control groupcomparison between 3 active treatment groups
3 arms study
COVID-19 mild to moderate
open-label
madrid, spain
prospective, phase II, randomized, open-label, 3 parallel groups study
no formal control groupcomparison between 3 active treatment groups
powered by vis.js Network